A Multicenter Study To Evaluate The Safety And Efficacy Of Heber On (Interferon Alfa-2b) In Combination With Ribavirin For The Treatment Of Chronic Hepatitis C In Iran

• Main Authors: H. Mirmomen, M. Azmi, M. Amirian, F. Mansourghanaei, M. Zahedi, H. Vosoghinia, M. Nasiri, M. Talebi, A. Ghavidel, N. Daryani, H. Ghofrani, M. Farahvash, H. Forootan, A. Sharifi, Sh. Mirmomen
• Format: Article
• Language: English
• Published: Iran University of Medical Sciences 2005-05-01
• Series: Medical Journal of The Islamic Republic of Iran
• Subjects: Interferon alfa-2b; Chronic Hepatitis C; Sustained VirologicalResponse; Side Effects
• Online Access: http://mjiri.tums.ac.ir/browse.php?a_code=A-10-1-253&slc_lang=en&sid=1

Combination therapy with interferon and ribavirin is the most effective treatment for chronic hepatitis C today. The aim of this study was to evaluate the efficacy and safety of thrice-weekly Heberon (interferon alfa-2b) in combination with ribavirin as first -line treatment of chronic hepatitis C. Methods: A total of97 treatment-naive patients received Heberon three million units thrice-weekly subcutaneously in combination with ribavirin for 12 months. Serum HCV RNA levels were measured before and during therapy and 6 months after the end of therapy. End-of-treatment and sustained virological responses was defmed as an undetectable HCV-RNA level at the end of treatment, and 6 months after treatment was completed (end of follow-up), respectively. Results: In an intent-to-treat analysis, HCV-RNA was undetectable at the end of treatment in 49.5% of patients. At the end of follow-up, sustained virological response was 36.1 %. Combination treatment was generally well tolerated. Six patients stopped therapy because of side effects: severe cytopenia (n=4), depression (n=1), and hyperthyroidism (n= 1 ). Common side effects of therapy include: Flu-like syndrome (85.6%), generalized alopecia (41.2% ), injection site inflammation (37.1% ), mood changes (36% ), anorexia (34%) and weight loss (32% ). Conclusion: Heberon as an IFN product in combination with ribavirin for treat-ment of patients with chronic hepatitis Cis relatively safe, feasible, and potentially efficacious. It has comparable results in achieving end-of-treatment and sustained virological responses in chronic hepatitis C.